NASDAQ NMS - GLOBAL MARKET · KTTA
+6.60% · +$0.0310 · Vol 302.7K
Market closed · last close 4:00 PM ET · price as of 19:29:38 ET
Pasithea Therapeutics Corp

Pasithea Therapeutics Corp

Biotechnology
$0.5010
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
Earnings absence reason unknown
KTTA
Pasithea Therapeutics Corp
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KTTA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KTTA catalysts
About Pasithea Therapeutics Corp
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
5
Country
US

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.4890
Day high
$0.5394
Day low
$0.4799
Previous close
$0.4700
52W high
$1.47
-65.92% from high
52W low
$0.2923
18% of range
Market cap
$18M
EPS
$-1.3500
Beta
0.43
Shares out
33.4M
Volume
302.7K
1.08× rel vol
Avg volume
280.8K
VWAP
$0.5068
Price history computed in-house
1W
+4.81%
1M
+10.11%
3M
-26.33%
1Y
-30.14%
YTD
-61.16%
SMA 50 $0.4967 · above
SMA 200 $0.7468 · below
52W position 18%

KTTA overview

Loading financial statements
Loading KTTA Form 4 filings
Public disclosures

Congress activity in KTTA

No receipt-qualified Congressional disclosure is present for KTTA in the cached public ledger.

Federal contracts

KTTA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KTTA in this window.
Lobbying spend

KTTA lobbying filings, year to date.

Registered lobbying filings matched to Pasithea Therapeutics Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KTTA in this window.
Loading news for KTTA
Analyst ratings
Sovereign unlock shows live analyst consensus for KTTA.
Options
Sovereign unlock shows live options positioning for KTTA.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.